Durata Therapeutics, Inc.: 10-Q filed 2012-11-09
What Durata Therapeutics, Inc. reported in its quarterly report filed 2012-11-09 (fiscal Q3 2012): 28 published measures, 83 facts as tagged in accession 0001193125-12-461924.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2012-11-09
- Fiscal period
- fiscal Q3 2012
- Accession
- 0001193125-12-461924 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Durata Therapeutics, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 95,592,432 | USD | |
| At 2011-12-31 | 33,624,816 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 38,723,891 | USD | |
| At 2011-12-31 | 22,064,821 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 56,868,541 | USD | |
| At 2011-12-31 | 5,559,995 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 60,789,676 | USD | |
| At 2011-12-31 | 11,485,266 | USD | |
| At 2011-09-30 | 21,432,522 | USD | |
| At 2010-12-31 | 2,264,145 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | -21,774,192 | USD | 92 |
| 2012-01-01 to 2012-09-30 | -49,219,456 | USD | 274 |
| 2009-11-07 to 2012-09-30 | -93,980,764 | USD | 1059 |
| 2011-07-01 to 2011-09-30 | -9,386,457 | USD | 92 |
| 2011-01-01 to 2011-09-30 | -23,264,224 | USD | 273 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-09-30 | 507,599 | USD | 274 |
| 2009-11-07 to 2012-09-30 | 507,599 | USD | 1059 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-09-30 | 93,520,287 | USD | 274 |
| 2009-11-07 to 2012-09-30 | 149,297,223 | USD | 1059 |
| 2011-01-01 to 2011-09-30 | 36,578,999 | USD | 273 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-09-30 | -1,357,599 | USD | 274 |
| 2009-11-07 to 2012-09-30 | -11,397,879 | USD | 1059 |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2009-11-07 to 2012-09-30 | -5,811,000 | USD | 1059 |
| 2011-07-01 to 2011-09-30 | -706,356 | USD | 92 |
| 2011-01-01 to 2011-09-30 | -1,488,645 | USD | 273 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 507,599 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | 398,655 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 1,082,258 | USD | 274 |
| 2009-11-07 to 2012-09-30 | 2,205,625 | USD | 1059 |
| 2011-07-01 to 2011-09-30 | 183,939 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 609,757 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | -21,785,724 | USD | 92 |
| 2012-01-01 to 2012-09-30 | -49,237,939 | USD | 274 |
| 2009-11-07 to 2012-09-30 | -99,828,127 | USD | 1059 |
| 2011-07-01 to 2011-09-30 | -10,094,936 | USD | 92 |
| 2011-01-01 to 2011-09-30 | -24,764,297 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 62,140,761 | USD | |
| At 2011-12-31 | 12,481,536 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 18,078,988 | USD | |
| At 2011-12-31 | 3,325,821 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 6,659,182 | USD | |
| At 2011-12-31 | 1,956,572 | USD |
Goodwill carrying amount
Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 5,811,000 | USD | |
| At 2011-12-31 | 5,811,000 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | 18,956,271 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 42,254,987 | USD | 274 |
| 2009-11-07 to 2012-09-30 | 77,403,913 | USD | 1059 |
| 2011-07-01 to 2011-09-30 | 8,325,872 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 21,093,744 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 18,358,082 | shares | |
| At 2011-12-31 | 62,500 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 150,665,724 | USD | |
| At 2011-12-31 | 49,828,699 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-12-31 | 40,280 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 8,578,734 | USD | |
| At 2011-12-31 | 1,369,249 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 1,351,085 | USD | |
| At 2011-12-31 | 996,270 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | -21,774,192 | USD | 92 |
| 2012-01-01 to 2012-09-30 | -49,219,456 | USD | 274 |
| 2009-11-07 to 2012-09-30 | -99,791,764 | USD | 1059 |
| 2011-07-01 to 2011-09-30 | -10,092,813 | USD | 92 |
| 2011-01-01 to 2011-09-30 | -24,752,869 | USD | 273 |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | 21,774,192 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 49,219,456 | USD | 274 |
| 2009-11-07 to 2012-09-30 | 93,980,764 | USD | 1059 |
| 2011-07-01 to 2011-09-30 | 9,386,457 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 23,264,224 | USD | 273 |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | 21,774,192 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 49,219,456 | USD | 274 |
| 2009-11-07 to 2012-09-30 | 93,980,764 | USD | 1059 |
| 2011-07-01 to 2011-09-30 | 9,386,457 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 23,264,224 | USD | 273 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | 2,552,453 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 6,165,952 | USD | 274 |
| 2009-11-07 to 2012-09-30 | 14,160,214 | USD | 1059 |
| 2011-07-01 to 2011-09-30 | 1,009,064 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 3,313,553 | USD | 273 |
Deferred income tax expense or benefit
The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2009-11-07 to 2012-09-30 | -5,811,000 | USD | 1059 |
| 2011-01-01 to 2011-09-30 | -1,488,645 | USD | 273 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-09-30 | 4,628,067 | USD | 274 |
| 2009-11-07 to 2012-09-30 | 6,584,639 | USD | 1059 |
| 2011-01-01 to 2011-09-30 | 1,140,442 | USD | 273 |
Inspect the source
- Entity
- Durata Therapeutics, Inc. / CIK 0001544116
- Captured
- SEC response SHA-256
b772cae7e439db4bda19a5aa54cd67ad4687936868a9d88fefea11e70429dd01
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001544116.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))